

DAFTAR PUSTAKA

- American Diabetes Association* (ADA). 2017. Standards of medical care in diabetes: Classification and diagnosis of diabetes. *Diabetes Care*, 41(1): 13-27.
- Amitrano L, Guardascione M, Brancaccio V, Balzano A. 2002. Coagulation disorders in liver disease. *Seminars in Liver Disease*, 22 (1):83-96.
- Arif S & Khan S. 2002. Changes in fibrinogen level in liver cirrhosis. *Journal Ayub Medical Collage Abbottaband*, 14 (2): 19-21.
- Arras D & John S. 2016. IL-6 pathway in the liver: from physiopathology to therapy. *Journal of Hepatology*, 30: 1-13. Available at: <http://dx.doi.org/10.1016/j.jhep.2016.02.004>. [Accessed 26 July 2018].
- Bacon B. 2013. Cirrhosis and its complications. In Longo D, Kasper D, Jameson J, Fauci A, Hauser S, Loscalzo J, *Gastroenterology and Hepatology Harrison's second Edition*. McGraw-Hill, United States.
- Bermejo JM, Esper RC, Uribe M, Sanchez N. 2013. Coagulation abnormalities in the cirrhotic patient. *Annals of Hepatology*, 12(5): 713-724.
- Bernardi M, Gitto S, Biselli M. 2011. The MELD score in patients awaiting liver transplant: Strength and weakness. *Journal of hepatology*, 54: 1297-1306.
- Berzigotti A. 2017. Advances and challenges in cirrhosis and portal hypertension. *BMC Medicine*, 15(200): 1-8.
- Botta F, Giannini E, Romagnoli P, Fasoli A, Chiarbonello B. 2003. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. *Gut*, 52:134–139.
- Brace L. 2001. Current status of the international normalized ratio. *Laboratory Medicine*, 7 (32): 390-392.
- Burroughs A. 2011. The Hepatic Artery, Portal Venous System and Portal Hypertension: the Hepatic Veins and Liver in Circulatory Failure. In Dooley JS, Lok A, Burroughs A, Heathcote E, *Sherlock's Diseases of the Liver and Biliary System twelfth Edition*. Blackwell Publishing, United States.
- Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A. 2006. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. *Hepatology*, 44(4):1039-1046.

- Caropeboka M. 2013. Ensefalopati hepatikum pada pasien sirosis hepatitis. *Jurnal Medula*, 1(4): 108-116.
- Carrie N, Ziol M, Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet J, Beaugrand M. 2006. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. *Hepatology*, 44: 1511-1517.
- Casadeall A & Pirofski L. 2000. Host-Pathogen Interactions: Basic Concepts of Microbial Commensalism, Colonization, Infection, and Disease. *Infection and Immunity*, 68(12): 6511–6518.
- Catena C, Zingaro L, Casaccio D, Sechi L. 2000. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. *The American Journal Of Medicine*, 109: 556-561.
- Caterino J. 2008. Infections in older adults. *Emergency Medical Clinics of North America*, 26(2): 319-343.
- Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. 1997. Coagulation and fibrinolysis changes in normal pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 73: 31-36.
- Chang P, Wong G, Li J, Lui H, Chow W, Tan C .2015. Epidemiology and clinical evolution of liver cirrhosis in Singapore. *Annual Academy Medicine of Singapore*, 44(6): 218-225.
- Chapin J & Hajjar K. 2015. Fibrinolysis and the control of blood coagulation. *Blood Reviews*, 29(1): 17–24.
- Corrigan M, Hirschfield GM, Oo YH, Adams DH. 2015. Autoimmune hepatitis: An approach to disease understanding and management. *British Medical Bulletin*, 114: 181-191.
- D’Amico G, Franchis R, Dell’Era A. 2014. Natural history and stages of cirrhosis and variceal hemorrhage. Springer Science Business Media, New York. Available at: http://DOI 10.1007/978-1-4939-0002-2_2. [Accessed 14 December 2017].
- Dahlan S. 2014. Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan, CV Sagung Seto, Jakarta.
- Das A, Dhiman R, Saraswat V, Verma M , Meera S. 2001. Chronic liver diseases: epidemiology, pathophysiology, diagnosis and treatment, prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. *Journal of Gastroenterology and Hepatology*, 16: 531–535.
- Davis R, Dorey S, Jenne C. 2016. Platelets and coagulation in infection. *Clinical and Translational Immunology*, 5(7): 1-7.

- Dhar A, Mullish B, Thursz M. 2017. Anticoagulant in chronic liver disease. *Journal of Hepatology*, 66: 1313-1326.
- Desborough MJR, Kahan BC, Stanworth SJ & Jairath V. 2017. Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding. *Hepatology*, 65(3):1079-1080.
- Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, Holzinger U, Zauner C, Schellongowski P. 2016. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. *Hepatology*, 64(2): 556-568.
- Durand F, Valla D. 2005. Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. *Journal of Hepatology*, 42:100–107.
- Falanga A, Marchetti M, Vignoli A. 2013. Coagulation and cancer: biological and clinical aspects. *Journal of Thrombosis Haemostasis*, 11: 223–233.
- Fattah M, Shaheen M, Mahfouz M. 2004. Disturbances of haemostasis in diabetes mellitus. *Disease Markers*, 19: 251–258.
- Feverly J. 2008. Bilirubin in clinical practice: a review. *Liver International*, 28(5): 592-605.
- Franchis RD. 2010. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *Journal of Hepatology*, 30(3):1-7.
- Francis B & Feinstein D. 1984. Clinical significance of accelerated fibrinolysis in liver disease. *Haemostasis*, 14: 460-465.
- Francoz C, Glotz D, Moreau R, Durand F. 2010. The evaluation of renal function and disease in patients with cirrhosis. *Journal of Hepatology*, 52: 605–613.
- Gado A, Ebeid B, Axon A. 2014. Prevalence and outcome of peptic ulcer bleeding in patients with liver cirrhosis. *Alexandria Journal of Medicine*, 50(2): 143-148.
- Giard J & Terrault N. 2016. Women with cirrhosis prevalence, natural history, and management. *Gastroenterology Clinics of North America*, 45(3): 345–358.
- Gold R. 2005. The implications of defining when a woman is pregnant. *The Guttmacher Report on Public Policy*. Available at https://www.guttmacher.org/sites/default/files/article_files/gr080207.pdf. [Accessed 31 January 2019].
- Gorp E, Suharti C, Cate H, Dolmans W, Cate J, Brandjes D. 1999. Review: Infectious diseases and coagulation disorders. *The Journal of Infectious Diseases*, 180(1): 176–186.

- Gotthardt D, Weiss K, Baumgärtner M, Zahn A, Stremmel W, Schmidt J. 2009. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. *BMC Gastroenterology*, 9(72): 1-10.
- Gunnarsdóttir S. 2008. Liver cirrhosis – Epidemiological and clinical aspects. Göteborg University. Göteborg, Sweden.
- Ha N & Regal R. 2012. Cirrhosis: Caught between a rock-liver and a hard place. *World Journal of Gastroenterology*, 18(24): 3035-3049.
- Hassan H, Ansari A, Memon S. 2017. Haemostasis abnormalities in patients with cirrhosis and their relationship with severity of liver dysfunction as assessed by childpugh score. *Journal of Liaquat university of medical & health science*, 16(02): 108-113.
- Heidelbaugh JJ & Bruderly M. 2006. Cirrhosis and chronic liver failure. *American Academy of Family Physicians*, 74(5): 767-776.
- Hejamdi M. 2010. Introduction to Cancer Biology second edition. Available at: <http://www.bookbon.com> [Accessed 14 December 2017].
- Higgins C. 2016. Urea and creatinine concentration, the urea: creatinine ratio. Available at: <http://www.acutecaretesting.org> [Accessed 19 January 2018].
- Husebø R, Gabazza E, D'Alessandro C, Aanerud M, Toda M, Grønseth R, Bakke P, Eagan T. 2018. Coagulation markers in COPD. *European Respiratory Journal*, 52(62): 1937-1938.
- Iris W, Liou M. 2017. Diagnosis and management of hepatic encephalopathy. *Hepatitis C online*, 3(4): 1-20.
- James P, Oparil S, Carter B, Cushman W, Himmelfarb C, Handler J, Lackland T. 2014. Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth joint national committee (JNC 8). *Journal of the American Medical Association*, 311(5): 507-520.
- Jiskani A, Memon S, Naseem L. 2017. Prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) as predictive factors of coagulopathy in newly diagnosed hypertensive patients. *Hematology & Transfusion International Journal*, 4(3): 1-5.
- Kamath PS & Kim WR. 2009. The international normalized ratio of prothrombin time in the MELD Score: a reliable measure. *Clinical Liver Disease*, 13(1): 63–66.

- Kidney Disease Improving Global Outcome (KDIGO)*. 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney international supplements*, 3(1): 1-163.
- Kim JA, Kim JE, Song SH, Kim HK. 2015. Influence of blood lipids on global coagulation test results. *Annual Laboratory Medicine*, 35:15-21.
- King M, Kingery J, Casey B. 2012. Diagnosis and evaluation of heart failure. *American Family Physician*, 85(12): 1161-1168.
- Kleinegris MC, Bos M, Roest M, Henskens Y, Hoek T, Deursen C, Spronk M. 2014. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. *Journal of Thrombosis and Haemostasis*, 12: 1647–1657.
- Kwong A, Lai J, Dodge J, Roberts J. 2015. Outcomes for liver transplant candidates listed with low MELD. *Liver Transplant*, 21(11): 1403–1409.
- Laskiewicz L, Fabricius W, Weinstein R. 2014. The Clinical Utility of Tranexamic Acid in the Management of Refractory Bleeding in a Patient With Advanced Liver Disease. *Journal of Hematology*, 3(2): 46-49.
- Lau T & Ahmad J. 2013. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. *Hepatic Medicine: Evidence and Research*, 5: 1-10.
- Leebeek F & Rijken D. 2015. The fibrinolytic status in liver diseases. *Seminars in Thrombosis and Hemostasis*, 41: 474–480.
- Lee JH, Kweon OJ, Lee MK, Lee HW, Kim HJ, Kim HR. 2015. Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease. *International Journal of Hematology*, 102:163–169.
- Levi M, Keller T, Gorp E, Cate H. 2003. Infection and inflammation and the coagulation system. *Cardiovascular Research*, 60: 26–39.
- Levy J. 2004. Hemostatic agent. *Transfusion*, 44: 58-62.
- Liaw Y & Sollano J. 2006. Factors influencing liver disease progression in chronic hepatitis B. *Liver International*, 26: 23-29.
- Lim J, Flamm S, Singh S, Yngve T, Ytter F. 2017. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. *Gastroenterology*, 152: 1536–1543.
- Lima L & Monteiro R. 2013. Activation of blood coagulation in cancer: Implications for tumour progression. *Bioscience Reports*, 33(5): 701-710.

- Lisman T & Ariëns S. 2016. Alterations in fibrin structure in patients with liver diseases. *Seminars in Thrombosis and Hemostasis*, 42(4): 389-396.
- Lisman T, Kleiss S, Patel V, Fisher C, Adelmeijer J, Bos S. 2018. In vitro efficacy of pro- and anticoagulant strategy in compensated and acutely ill patient with cirrhosis. *Liver International*. Available at: <http://doi.org/10.1111/liv.13882>. [Accessed 27 July 2018].
- Lorenzo F, Saba N, Kakkar V. 2003. Blood coagulation in patients with chronic heart failure evidence for hypercoagulable state and potential for pharmacological intervention. *Drugs*, 63(6): 565-576.
- Lovina A, Miro S, Efrida. 2017. Karakteristik pasien sirosis hepatitis di RSUP DR. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 6(1): 5-12. Available at <http://jurnal.fk.unand.ac.id>. [Accessed 31 January 2019].
- Lowe D, Rumley A, Mackie I. 2004. Plasma fibrinogen. *Annals of Clinical Biochemists*, 41: 430–440.
- Maat M, Nieuwenhuizen W, Knot E, Buuren H. 1995. Measuring plasma fibrinogen levels in patients with Liver cirrhosis. The occurrence of proteolytic Fibrin(ogen) degradation products and their influence on several fibrinogen assays. *Thrombosis research*, 78(4): 353-362.
- Madan R, Gupta B, Saluja S, Kansra U, Tripathi B, Guliani B. 2010. Coagulation profile in diabetes and its association with diabetic microvascular complications. *Journal Association of Physicians India*, 58: 481-484.
- Maity SG. 2012. Autoimmune hepatitis-better understanding. *Medicine Update*, 22: 463-468.
- Mallet M, Rudler M, Thabut D. 2017. Variceal bleeding in cirrhotic patients. *Gastroenterology Report*, 5(3): 185–192.
- Mari D, Ogliari G, Castaldi D, Vitale G, Bollini E, Lio D. 2008. Hemostasis and ageing. *Immunity & Ageing*, 5(12): 1-4.
- Marselina N. 2014. Gambaran klinis pasien sirosis hati: Studi kasus di RSUP DR Kariadi Semarang periode 2010-2012. *Jurnal media medika muda*: 1-15. Available at: <https://ejournal3.undip.ac.id/index.php/medico/article/view/7838/7594>. [Accessed 6 February 2019].
- Marzano A, Tedeschi A, Polloni I, Crosti C, Cugno M. 2012. Interactions between inflammation and coagulation in autoimmune and immune-mediated skin diseases. *Current Vascular Pharmacology*, 10(2): 647-652.
- Maus G & Hajjar K. 2005. Molecular mechanisms of fibrinolysis. *British Journal of Haematology*, 129: 307–321.

- Mavrogiannaki AN & Migdalis IN. 2013. Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. *International Journal of Endocrinology* Article ID 450639. Available at: <http://dx.doi.org/10.1155/2013/450639>. [Accessed 23 March 2017].
- McCormick P, Ooi H, Crosbie O. 1998. Tranexamic acid for severe bleeding gastric antral vascular ectasia in cirrhosis. *Gut*, 42: 750–752.
- Mosesson M. 2010. Fibrinogen functions and fibrin assembly. *Fibrinolysis & Proteolysis*, 14(2):182–186.
- Nadim M, Durand F, Kellum J, Levitsky J, O’Leary J, Karvellas J, Davenport A. 2016. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. *Journal of Hepatology*, 64: 717–735.
- Nasir MA, Ratnasari N, Bayupurnama P. 2013. Relationship between plasma fibrinogen levels with *Model for End Stage Liver Disease* score in patients with liver cirrhosis. *Acta Interna - The Journal of Internal Medicine*, 3(2): 10-15.
- National Cholesterol Education Program (NCEP). 2001. ATP III Guidelines at-a-glance quick desk reference. Available at <https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf>. [Accessed 30 January 2019].
- Nganjeu H. 2017. Hepatic encephalopathy in liver cirrhosis. *Journal of Translational Internal Medicine*, 5(1):64-67.
- Oey R, Buuren H, Man R. 2016. The diagnostic work-up in patients with ascites: current guidelines and future prospects. *The Netherlands Journal of Medicine*, 74(8): 330-335.
- Pandey J & Prasad C. 2016. Study of acute phase proteins in liver disease. *Asian Journal of Biomedical and Pharmaceutical science*, 6(53): 35-36.
- Palta S, Saroa R, Palta A. 2014. Overview of the coagulation system. *Indian Journal of Anaesthesiology*, 58(5): 515-523.
- Peng Y, Qi X, Dai J, Li H, Guo X. 2015. Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis. *International Journal of Clinical and Experimental Medicine*, 8(1):751-757.
- Perhimpunan Peneliti Hati Indonesia (PPHIa). 2017. Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia. PPHI, Jakarta.
- Perhimpunan Peneliti Hati Indonesia (PPHIb). 2017. Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia. PPHI, Jakarta.

- Peterson J. 1996. Bacterial pathogenesis. In *Medical microbiology Chapter 7 forth edition*. University of Texas Medical Branch at Galveston, Texas. Available at <https://www.ncbi.nlm.nih.gov/pubmed/21413346>. [Accessed 30 January 2019].
- Perz J, Armstrong G, Farrington L, Hutin Y, Bell B. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of Hepatology*, 45: 529–538.
- Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, Durand F, Francque S, Bezeaud A, Chauvelot L, Lebrech D, Valla DC, Moreau R. 2003. Coagulation disorders in patients with cirrhosis and severe sepsis. *Liver International*, 23: 440–448.
- Prinsen B, Rabelink T, Beutler J, Kaysen G, Boer J, Hagen C. 2003. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. *Kidney International*, 64: 1495-1504.
- Procopet B & Berzigotti A. 2017. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. *Gastroenterology Report*, 5(2): 79–89.
- Roberts I, Coats T, Edwards P, Gilmore I, Jairath P, Kerl K, Shakur H, Stanworth S, Veitch A. 2014. HALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. *Trials*, 15(450): 1-15.
- Roche S, Kobos R. 2004. Jaundice in the adult patient. *American Family Physician*, 69(2): 299-304.
- Saienko V & Konopkina L. 2014. The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD). *European Respiratory Journal*, 44 (58): 4732-4733.
- Saracco P, Vitale P, Scolfaro C, Pollio B, Pagliarino M, Timeus F. 2011. The Coagulopathy in sepsis: Significance and implications for treatment. *Pediatric Reports*, 3(30):119-121.
- Sarin S, Angus P, Baijal S, Baik S, Bayraktar Y, Chawla Y, Choudhuri G. 2011. Diagnosis and management of acute variceal bleeding: Asian pacific association for study of the liver recommendations. *Hepatology International*, 5: 607–624.
- Schuppan D & Afdhal N. 2008. Liver cirrhosis. *Lancet*, 371: 838–851.
- Shah N & Caldwell S. 2016. Assessing the risk of bleeding and clotting in cirrhosis. *Clinical liver disease*, 7(2):26-28.
- Shahna S, Gopalakrishnan P, Devadas K, Sriyaya K, Shanid P, Babu G, Iyer S, Yadav S, Peter G. 2016. MELD VS MELD Na for predicting in-hospital

- mortality in decompensated chronic liver disease. *Cirrhosis And Complications*. Available at <http://dx.doi.org/10.1016/j.jceh.2016.06.074>. [Accessed 31 January 2019].
- Shao Z, Zhao Y, Feng L, Feng G, Zhang J. 2015. Association between plasma fibrinogen levels and mortality in acute on chronic hepatitis B liver failure. *Disease Markers* Article ID 468596: 1-6. Available at: <http://dx.doi.org/10.1155/2015/468596>. [Accessed 09 December 2017].
- Singer M, Deutschman C, Seymour C, Hari M, Annane D, Bauer M, Bellomo R. 2016. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *Journal of American Medical Association*, 315(8): 801-810.
- Slack A, Yeoman A, Wendon J. 2010. Renal dysfunction in chronic liver disease. *Critical Care*, 14 (214): 1-10.
- Solymoss S. 2011. Risk of venous thromboembolism with oral contraceptive. *Canadian Medical Association Journal*, 183(18): 1278-1279.
- Sood R. 2003. Ascites: diagnosis and management. *Journal of Indian Academy of Clinical Medicine*, 5(1): 81-89.
- Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S. 2006. Buku ajar ilmu penyakit dalam. Jilid I. Edisi ke-4. Jakarta: Balai Penerbitan IPD Fakultas Kedokteran Universitas Indonesia. p 427-453.
- Patasik Y, Walelang B, Wantania F. 2015. Profil pasien sirosis hati yang dirawat inap di RSUP PROF. DR. R. D. Kandou Manado periode agustus 2012 – agustus 2014. *Jurnal e-Clinic*, 3(1): 342-347.
- Thabut D, D'Amico G, Tan P, De Franchis R, Fabricius S, Lebrech D Bosch J, Bendtsen F. 2010. Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding. *Journal of Hepatology*, 53: 1029–1034.
- Thakrar SV & Mallett SV. 2017. Thrombocytopenia in cirrhosis: impact of fibrinogen on bleeding risk. *World Journal of Hepatology*, 9(6): 318-325.
- Thapa B & Walia A. 2007. Liver function tests and their interpretation. *Indian Journal of Pediatrics*, 74: 663-671.
- Trenor C, Chung R, Gordon C, Michelson A, Neufeld E, Laufer M, Emans S. 2011. Hormonal contraception and thrombotic risk: a multidisciplinary approach. *Pediatrics*, 127(2): 347–357.
- Tripodi A & Mannucci PM. 2011. The coagulopathy of chronic liver disease. *The New England Journal of Medicine*, 365(2):147-56.

- Trotter JF, Olson J, Lefkowitz J, Smith D, Arjal R, Kenison J. 2007. *American Journal of Transplantation*, 7: 1624–1628.
- Tsao C, Ho S, Wu C. 2014. Coagulation abnormalities in sepsis. *Acta Anaesthesiologica Taiwanica* 30: 1-7. Available at [http:// dx.doi.org/10.1016/j.aat.2014. 11.002](http://dx.doi.org/10.1016/j.aat.2014.11.002). [Accessed 09 December 2017].
- Tsochatzis EA, Bosch J, Burroughs AK. 2014. Liver cirrhosis. *The Lancet*, 383(9930): 1749-1761. Available at [http://dx.doi.org/10.1016/ S0140-6736\(14\)60121-5](http://dx.doi.org/10.1016/S0140-6736(14)60121-5). [Accessed 09 December 2017].
- Undas A, Jankowski M, Kaczmarek P, Sladek K, Ziedins K. 2011. Thrombin generation in chronic obstructive pulmonary disease:dependence on plasma factor composition. *Thrombosis Researchs*, 128(4): 24 – 28.
- Valla D & Rautou P. 2015. The coagulation system in patients with end-stage liver disease. *Liver International*, 35(1): 139-144.
- Vila E. 2015. A review of the JNC 8 blood pressure guideline. *Texas Heart Institute Journal*, 42(3): 226-228.
- Werdan K, Dullaes R, Presek P. 2013. Anticoagulation in atrial fibrillation: NOAC's the World. *Deutsches Ärzteblatt International*, 110(31): 523–524.
- Winger J & Michelfelder A. 2011. Diagnostic approach to the patient with jaundice. *Primary Care Clinics in Office Practice*, 38: 469–482.
- World Health Organization (WHO). 2000. Asia-pacific perspective redefining obesity and its treatment. Available at <http://www.wpro.who.int/nutrition/documents/docs/Redefiningobesity.pdf>. [Accessed 30 January 2019].
- World Health Organization (WHO). 2004. Contraception issues in adolescent health and development. Available at https://apps.who.int/iris/bitstream/handle/10665/9019241591447_eng.pdf;jsessionid=39293068AD813A305C9ECF3D0CCDB23A?sequence=1. [Accessed 30 January 2019].
- World Health Organization (WHO). 2016. Global health sector strategy on viral hepatitis 2016-2021, towards ending viral hepatitis.
- Wiegand J & Berg T. 2013. Review article: The etiology, diagnosis and prevention of liver cirrhosis - part 1 of a series on liver cirrhosis. *Deutsches Ärzteblatt International*, 110(6): 85–91.
- Wiesner R, Edwards E, Freeman R, Harper A, Kim R. 2003. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology*, 124: 91–96.